The role of long non-coding RNA FGD5-AS1 in cancer

He, Na; Xiang, Linbiao; Chen, Lei; Tong, Hao‐Bin; Wang, Keshen; Zhao, Jie; Song, Fang; Yang, Hanwei; Wei, Xinyuan; Zhang, Jiao

doi:10.1080/21655979.2022.2067292

Cited by 8 publications

(4 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although long non-coding RNAs (lncRNAs) do not encode proteins, they can regulate the expression of downstream target protein-coding genes through a variety of mechanisms. Especially for cancer, dysregulation of lncRNAs is associated with various malignant phenotypes and leads to cancer progression and metastasis [ 39 ]. Therefore, the differential expression of miR-4443 in different diseases may be related to the regulation of ceRNA.…”

Section: Discussionmentioning

confidence: 99%

Aberrant expression of microRNA-4443 (miR-4443) in human diseases

Mao

Shen

et al. 2022

Bioengineered

View full text Add to dashboard Cite

miRNA is a small endogenous RNA and an important regulator of gene expression. miR-4443 is abnormally expressed in 12 diseases including cancer. The expression of miR-4443 is regulated by 3 upstream factors. miR-4443 has 12 downstream target genes. miR-4443 inhibits the expression of its target genes, thereby affecting the migration, proliferation, and invasion of pathological cells. miR-4443 participates in 4 signaling pathways and plays a role in the occurrence and development of several diseases. In addition, miR-4443 can also promote resistance to multiple drugs. Here, this article summarizes the aberrant expression of miR-4443 and its pathogenic molecular mechanisms in human diseases, which provides clues and directions for the follow-up research of miR-4443.

show abstract

Section: Discussionmentioning

confidence: 99%

Aberrant expression of microRNA-4443 (miR-4443) in human diseases

Mao

Shen

et al. 2022

Bioengineered

View full text Add to dashboard Cite

show abstract

“…FGD5-AS1, a newly discovered lncRNA with a length of 3772 nucleotides, is abnormally overexpressed in various cancer tissues and closely associated with lymph node metastasis, tumor invasion, survival time, and recurrence rate [ 187 ]. In the progression of CRC, lncRNA FGD5-AS1 upregulates CDCA7 expression by competitively inhibiting miR-302e, promoting the proliferation, migration, and invasion capabilities of CRC cells [ 188 ].…”

Section: Non-coding Rnasmentioning

confidence: 99%

Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications

Cao,

Tian,

Deng

et al. 2024

IJMS

View full text Add to dashboard Cite

Colorectal cancer (CRC), a prevalent malignant tumor of the digestive system, ranks as the third and second in global incidence and mortality, respectively, in 2020, with 1.93 million new cases (≈10% of all cancers). There are 940,000 deaths (≈9.4% of all cancers), and the incidence of CRC in younger patients (under 50 years of age) has become a new trend. The pathogenesis of CRC is primarily attributed to a series of genetic and epigenetic abnormalities within normal colonic epithelial cells, coupled with the reshaping of the tumor microenvironment in the surrounding stroma. This process leads to the transformation of colorectal adenomas into invasive adenocarcinomas. Although genetic changes are known to be the primary driving force in the occurrence and progression of CRC, recent research indicates that epigenetic regulation serves as a crucial molecular marker in cancer, playing a significant role in the pathological and physiological control of interactions between genetics and the environment. This review discusses the current global epidemiology of CRC, its risk factors, and preventive treatment strategies. The current study explores the latest advancements in the epigenetic regulation of CRC, including DNA methylation, histone modifications, and non-coding RNAs (ncRNAs). These developments hold potential as screening tools, prognostic biomarkers, and therapeutic targets for CRC.

show abstract

“…Although early screening and prevention efforts have helped to improve the survival of patients with ESCA, the 5-year overall survival (OS) rate of patients with advanced ESCA remains <20% ( 60 , 61 ). The high mortality and low survival rates of ESCA are currently a major challenge for clinical practitioners and exploring novel biomarkers for prognostic analysis is an important topic in ESCA research ( 62 ). Feng et al ( 63 ) detected a trend toward decreased expression of the lncRNA FAM83H-AS1 in ESCC tissues and cells.…”

Section: Lncrnas and Cancermentioning

confidence: 99%

Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review)

et al. 2023

View full text Add to dashboard Cite

With advancements in sequencing technologies, an increasing number of aberrantly expressed long-non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) have been identified in various types of cancer. lncRNAs and circRNAs are now well-established tumor-influencing factors in cancer, driving not only tumor proliferation and invasion, but also cancer progression, drug resistance and metastatic recurrence. The majority of lncRNAs and circRNAs influence cancer progression by targeting microRNAs (miRNAs/miRs). miR-10a and miR-10b, key members of the miR-10 family, have been shown to play important regulatory roles in cell proliferation, differentiation to cancer progression, and development. Manual evaluation and grouping according to different types of competing endogenous RNA and tumor was performed. The review outlined the current state of knowledge on the regulation of miR-10 family-related lncRNAs and circRNAs. The involvement of lncRNAs and circRNAs in the biogenesis, maturation and function of malignant tumors through the miR-10 family, and the key gene targets and signaling cascades that lncRNAs and circRNAs regulate through the miR-10 family were summarized. Based on the findings of this review, it can be hypothesized that lncRNAs and circRNAs targeting the miR-10 family may serve as diagnostic/prognostic markers and/or therapeutic targets for the management of cancer.

show abstract

The role of long non-coding RNA FGD5-AS1 in cancer

Cited by 8 publications

References 98 publications

Aberrant expression of microRNA-4443 (miR-4443) in human diseases

Aberrant expression of microRNA-4443 (miR-4443) in human diseases

Epigenetic Alteration in Colorectal Cancer: Potential Diagnostic and Prognostic Implications

Advances in targeting of miR‑10‑associated lncRNAs/circRNAs for the management of cancer (Review)

Contact Info

Product

Resources

About